NCT01730456View on ClinicalTrials.gov

A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926

PHASE3CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg iv every 4 weeks, up to 104 weeks

Trial Locations (1)

1000

Skopje

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01730456 - A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926 | Biotech Hunter | Biotech Hunter